91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Feasibility, site selection and study startup are among the most complex areas of clinical development, yet they remain stubbornly inefficient. 91黑料’s Brian Mallon explores how sponsors and CROs are leveraging AI, predictive analytics and integrated data environments for faster, more predictable trial delivery and stronger site partnerships. .
-
In this article, learn how sponsors can drive multi-indication success through strategic trial design, early cross-functional planning, and evidence-driven development.
-
Read the article to learn why the exclusion of pregnant women from clinical trials continues to fuel data gaps, misinformation, and missed opportunities for safer, more effective treatments.
-
Conducting a high-quality, clinically relevant literature review can be challenging – it demands strategic thinking, methodological rigour and therapeutic expertise. 91黑料 expert Rebecca Rozich explains why systematic literature reviews can be a powerful alternative to generating new data.
-
In the October issue of PharmaTimes, Dr. Quintin van Wyk considers the importance of post-marketing pharmacovigilance, and explains how carefully applied automation and AI can strengthen adverse event reporting and causality assessment while keeping patient safety and regulatory compliance central.
-
ICH GCP E6(R3) is here. In the latest issue of PharmaTimes, 91黑料 explores why a comprehensive impact assessment is the essential first step toward strategic compliance.
-
Dr. Liz O’Brien, Senior Director of Global Drug Development at 91黑料 and former EMA regulator, joined the BioCentury This Week podcast to share insights on navigating FDA’s Project Optimus, the EMA’s Joint Clinical Assessment and highlight the key differences between the two regulatory regimes.
-
A recent 91黑料 survey found fewer than 15% of sponsors use RWE to inform their multi-indication development strategy for obesity-related drugs. Learn best practices for leveraging RWE for GLP-1 based therapies in our article.
-
91黑料's new CEO, Barry Balfe, speaks to BioXconomy on industry challenges - and opportunities - ahead.
-
91黑料 experts, Pierre Martineau and Adrienne Stoudenmire, share key considerations for successful CVOTs including study design, data strategy and technology in this new article.
